Recurrence and survival of patients with stage III endometrial cancer after radical surgery followed by adjuvant chemo- or chemoradiotherapy: a systematic review and meta-analysis

BMC Cancer

Research

Jia-ying Ruan¹  Jin-ke Li¹  Yu Fan²  Si-yu Cao²  Yu-fei Zhang²  Yi Mu³ 

[1] Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University, No. 20, Section 3, Renminnan Road, 610041, Chengdu, Sichuan, China;Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University, No. 20, Section 3, Renminnan Road, 610041, Chengdu, Sichuan, China;Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Sichuan University, Chengdu, People’s Republic of China;Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Sichuan University, Chengdu, People’s Republic of China;

关键词: Endometrial cancer;    Chemotherapy;    Radiotherapy;    Chemoradiotherapy;    Meta-analysis;   

DOI  :  10.1186/s12885-022-10482-x

 received in 2022-08-26, accepted in 2022-12-23,  发布年份 2022

来源: Springer

【 摘 要 】

ObjectiveTo compare recurrence and survival in patients with stage III endometrial cancer after radical surgery, followed by either adjuvant chemoradiotherapy (ACR) or adjuvant chemotherapy (AC).MethodsWe searched for relevant studies in PubMed Central, Embase and the Cochrane Central Register of Controlled Trials. Data were pooled on rates of recurrence as well as rates of progression-free, disease-free and overall survival. Heterogeneity was evaluated using the I2 test. Subgroup and sensitivity analyses were performed to identify potential sources of heterogeneity.ResultsData from 18,375 patients in 15 retrospective studies and one randomized controlled trial were meta-analyzed. Compared to the AC group, the ACR showed significantly lower risk of local recurrence (OR 0.43, 95%CI 0.32–0.59) and total recurrence (OR 0.72, 95%CI 0.58–0.89). ACR was also associated with significantly better overall survival (HR 0.66, 95%CI 0.57–0.76), progression-free survival (HR 0.56, 95%CI 0.39–0.81) and disease-free survival (HR 0.66, 95%CI 0.53–0.83).ConclusionsAdding adjuvant radiotherapy to adjuvant chemotherapy after radical surgery may significantly reduce risk of local and overall recurrence, while significantly improving survival of patients with stage III endometrial cancer.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

41116_2022_35_Article_IEq535.gif

41116_2022_35_Article_IEq533.gif

41116_2022_35_Article_IEq530.gif

41116_2022_35_Article_IEq528.gif

41116_2022_35_Article_IEq525.gif

Fig. 1